Keyphrases
Irinotecan
100%
Metastatic Colorectal Cancer (mCRC)
100%
Phase I Trial
100%
Dose Level
100%
Guadecitabine
100%
SGI-110
100%
Growth Factor Support
37%
Neutropenic Fever
25%
Tolerability
12%
Neutropenia
12%
Disease Progression
12%
Leukopenia
12%
Circulating Tumor DNA (ctDNA)
12%
Stable Disease
12%
Partial Response
12%
Previously Treated
12%
Demethylation
12%
Gene Silencing
12%
Promoter Methylation
12%
Resistance Mechanisms
12%
Dose-limiting Toxicity
12%
Chemotherapy Resistance
12%
Gastrointestinal Cancer
12%
Dose-escalation Study
12%
Best Response
12%
Epigenetic Therapy
12%
Infectious Dose
12%
Hypomethylating Agents
12%
Randomized multicenter Trial
12%
Severe Dehydration
12%
Injection Site Reaction
12%
Early Indication
12%
Colonic Obstruction
12%
Biliary Drain
12%
Pharmacology, Toxicology and Pharmaceutical Science
Irinotecan
100%
Metastatic Colorectal Cancer
100%
Phase I Trials
100%
Guadecitabine
100%
Growth Factor
37%
Febrile Neutropenia
25%
Disease
12%
Disease Exacerbation
12%
Tolerability
12%
Infection
12%
Neutropenia
12%
Obstruction
12%
Leukopenia
12%
Digestive System Cancer
12%
Injection Site Reaction
12%
Circulating Tumor DNA
12%